Xoma (us) LLC

Gilead Sciences, Inc.

Xoma Technology Ltd.

Trishula Therapeutics, Inc.

Xoma Corporation

John Corbin

Mark Leslie White

Vinay Bhaskar

Susan R Watson

Brian A Carr

Nathan D Thomsen

Craig S Pace

Xue Zhang

Mini Balakrishnan

Daniel H Bedinger

Kirk William Johnson

Toshihiko Takeuchi

Marina Roell

Vanessa Soros

Robert Bauer

Ou Li

Hassan Issafras

Kiranjit Kaur Ahluwalia

Paul Rubin

Paul Fredrick Widboom

Joseph Robert Warfield

Ira Goldfine

Courtney Beers

Maria Kovalenko

Antibodies that modulate insulin receptor signaling are provided.

Modulators

The present invention provides novel anti-HIV antibodies with improved therapeutic properties, related pharmaceutical compositions, and methods of use thereof.

Human immunodeficiency virus neutralizing antibodies

Provided herein are antibodies that selectively bind to CD39 and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.

Anti-CD39 antibodies

The present disclosure relates, in general, to methods of treating or preventing hypoglycemia using a negative modulator antibody fragment that binds to the insulin receptor and modulates the action of insulin at the insulin receptor.

Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia

The present invention provides polypeptide binding agents, e.g. antibodies, that exhibit the ability to kinetically modulate the binding and signaling of biological signaling complexes, e.g., receptor-ligand complexes; methods of identifying such polypeptide binding agents, methods of making such polypeptide binding agents, compositions comprising such polypeptide binding agents, and methods of using such polypeptide binding agents.

Screening methods

Growing community of inventors

Oakland, CA, United States of America

John Corbin